Individualized therapy for osteoporosis prevention and treatment in women under 60

Climacteric

Volumn 12, Issue 3, 2009, Pages 210-212

  De Villiers, T J ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Bisphosphonates; Estrogens; Hormone Therapy; Osteoporosis; Raloxifene; Strontium Ranelate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; GESTAGEN; IBANDRONIC ACID; RALOXIFENE; STRONTIUM RANELATE;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG EFFECT; ESOPHAGUS CANCER; FRACTURE; HEART ATRIUM FIBRILLATION; HORMONE SUBSTITUTION; HUMAN; JAW OSTEONECROSIS; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; SHORT SURVEY; STROKE; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; VERTEBRA FRACTURE; CHEMICALLY INDUCED DISORDER; ESTROGEN THERAPY; FEMALE; MEDICAL SOCIETY; MIDDLE AGED; NOTE; POSTMENOPAUSE OSTEOPOROSIS; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM;

CORONARY ARTERY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT; SOCIETIES, MEDICAL; STROKE; VENOUS THROMBOEMBOLISM;

EID: 68949135642     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130902937644     Document Type: Short Survey

References (13)

1. Studd J. Estrogens as first-choice therapy for osteoporosis prevention and treatment in women under 60. Climacteric 2009;12:206-209
2. Pines A, Sturdee DW, Birkhäuser MH, et al. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181-194 (Pubitemid 46752441)
3. Anderson GL, Limacher M, Assaf AR, et al. The Women's Health Initiative Steering Committee. Effects of conjugated estrogen on postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712
4. Reginster JY. Strontium ranelate: 8 years efficacy on vertebral and non-vertebral fractures in postmenopausal osteoporotic women. Osteoporos Int 2008;19:S131-2
5. Kanis JA, Johnell O, Black DM, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: A reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 2003;33:293-300
6. Siris ES, Simon JA, Barton IP, et al. Effects of risedronate on fracture risk in postmenopausal women with osteopenia. Osteoporos Int 2008; 19:681-686
7. Rizzoli R, Felsenberg D, Laroche M, et al. Strontium ranelate has a more positive influence than alendronate on distal tibia cortical and trabecular bone microstructure in women with postmenopausal osteoporosis. Osteoporos Int 2008;19(Suppl 2):S233-50
8. Barrett-Connor E, Mosca L, Collins P. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137 (Pubitemid 44050394)
9. Collins P, Mosca L, Geiger MJ, et al. Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial. Results of a subgroup analyses by age and other factors. Circulation 2009;119:922-930
10. Schneider JP. Bisphosphonates and low-impact femoral fractures: Current evidence on alendronate- fracture risk. Geriatrics 2009;64:18-23
11. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009;360:89-90
12. Lee HY. Strontium ranelate-induced toxic epidermal necrolysis in a patient with postmenopausal osteoporosis. Osteoporos Int 2009; 20:161-162
13. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;2971465-2971477